Graves Orbitopathy Market, 2012-2023

January 2018 | 204 pages | ID: GD5629B1170EN
Precision Business Insights (PBI)

Abstracts

Global Graves Orbitopathy Market

Graves’ ophthalmopathy is also called as thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves’ orbitopathy (GO) is autoimmune inflammatory disorder of the tissues of periorbit and orbit that is characterized by the retraction of upper eyelid, lagging, swelling and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in the individuals having Graves’ disease, and less commonly in the individuals having Hashimoto’s thyroiditis, or in the people with euthyroid. It is a part of systemic process of variable expression in skin, thyroid and eyes that is caused by the autoantibodies which binds to the tissues of these organs. Autoantibodies targets the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expands and get inflammation.

Increase in incidence and prevalence of thyroid disorders, availability of appreciative reimbursement policies for the treatment, and growing awareness regarding the complications related to thyroid disorders are some of the factors driving Graves’ disease market. Side effects associated with drugs are one of the restraints for the graves orbitopathy market.

The global graves orbitopathy market is segmented on the basis of drug class, distribution channel and geographical regions.

Based on the drug class, the graves orbitopathy market is segmented as:

• Iodine and Iodides
• Ionic Inhibitors
• Radioactive Iodine
• Beta Blockers
• Thioamides
• Corticosteroids

Based on the distribution channel, the graves orbitopathy market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Others

As per Wickham study in England, in 2016, Graves’ disease is accounted for 0.5 cases per 1000 persons, with high incidence rate in people with age of 40 to 60. Graves’ disease is the high prevalent autoimmune disorder in U.S After Hashimoto thyroiditis. In 2016, as per research study of PREGO (presentation of Graves orbitopathy), incidence of Graves’ orbitopathy in Europe was 10-30/10,000 human annually. However, severity and the incidence of the Graves’ disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) used to remove whole or a part of thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of thyroid gland is the most invasive treatment option.

On the basis of geographical regions, the graves’ orbitopathy market is segmented as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected as major market for the disorders related to thyroid gland followed by Europe. Asia-Pacific is expected to be as a rapidly growing market due to rise in thyroid gland disorders, rise in health care investments, growing awareness regarding hyperthyroidism, and different alternative treatments availability.

Some of the players in the graves orbitopathy disease market are GlaxoSmithKline plc (U.K.), Allergan, plc.(Ireland) Abbott Laboratories (U.S.) RLC LABS (U.S.), AbbVie, Inc.( U.S.), Mylan N.V.( U.S.), Pfizer, Inc. (U.S.), and Merck & Co.,Inc. (U.S.)

In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with US $10 Mn each in series a financing and R&D support companies include Silarus Therapeutics- developing treatments for anaemia and iron overload disorders and Thyritope Biosciences- developing treatments for grave’s orbitopathy

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL GRAVES ORBITOPATHY MARKET INTRODUCTION

2.1. Global Graves Orbitopathy Market – Taxonomy
2.2. Global Graves Orbitopathy Market –Definitions
  2.2.1. Drug Class
  2.2.2. Distribution Channel

3. GLOBAL GRAVES ORBITOPATHY MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graves Orbitopathy Market Dynamics – Factors Impact Analysis
3.6. Global Graves Orbitopathy Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL GRAVES ORBITOPATHY MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Iodine and Iodides
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Ionic Inhibitors
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Radioactive Iodine
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Thioamides
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Corticosteroids
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL GRAVES ORBITOPATHY MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospital Pharmacies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL GRAVES ORBITOPATHY MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2017 – 2023

8. NORTH AMERICA GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.1.1. Iodine and Iodides
  8.1.2. Ionic Inhibitors
  8.1.3. Radioactive Iodine
  8.1.4. Beta Blockers
  8.1.5. Thioamides
  8.1.6. Corticosteroids
8.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  8.2.1. Hospital Pharmacies
  8.2.2. Retail Pharmacies
  8.2.3. Others
8.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  8.3.1. U.S.
  8.3.2. Canada
8.4. North America Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
8.5. North America Graves Orbitopathy Market Dynamics – Trends

9. EUROPE GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Iodine and Iodides
  9.1.2. Ionic Inhibitors
  9.1.3. Radioactive Iodine
  9.1.4. Beta Blockers
  9.1.5. Thioamides
  9.1.6. Corticosteroids
9.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Hospital Pharmacies
  9.2.2. Retail Pharmacies
  9.2.3. Others
9.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Germany
  9.3.2. UK
  9.3.3. France
  9.3.4. Spain
  9.3.5. Italy
  9.3.6. Russia
  9.3.7. Poland
  9.3.8. Rest of Europe
9.4. Europe Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2017 – 2023
9.5. Europe Graves Orbitopathy Market Dynamics – Trends

10. ASIA-PACIFIC GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Iodine and Iodides
  10.1.2. Ionic Inhibitors
  10.1.3. Radioactive Iodine
  10.1.4. Beta Blockers
  10.1.5. Thioamides
  10.1.6. Corticosteroids
10.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Hospital Pharmacies
  10.2.2. Retail Pharmacies
  10.2.3. Others
10.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Japan
  10.3.2. China
  10.3.3. India
  10.3.4. ASEAN
  10.3.5. Australia & New Zealand
  10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2017 – 2023
10.5. Asia-Pacific Graves Orbitopathy Market Dynamics – Trends

11. LATIN AMERICA GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Iodine and Iodides
  11.1.2. Ionic Inhibitors
  11.1.3. Radioactive Iodine
  11.1.4. Beta Blockers
  11.1.5. Thioamides
  11.1.6. Corticosteroids
11.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Hospital Pharmacies
  11.2.2. Retail Pharmacies
  11.2.3. Others
11.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Brazil
  11.3.2. Mexico
  11.3.3. Argentina
  11.3.4. Venezuela
  11.3.5. Rest of Latin America
11.4. Latin America Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2017 – 2023
11.5. Latin America Graves Orbitopathy Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA GRAVES ORBITOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Iodine and Iodides
  12.1.2. Ionic Inhibitors
  12.1.3. Radioactive Iodine
  12.1.4. Beta Blockers
  12.1.5. Thioamides
  12.1.6. Corticosteroids
12.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Hospital Pharmacies
  12.2.2. Retail Pharmacies
  12.2.3. Others
12.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Gulf Cooperation Council (GCC) Countries
  12.3.2. Israel
  12.3.3. South Africa
  12.3.4. Rest of MEA
12.4. MEA Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2017 – 2023
12.5. MEA Graves Orbitopathy Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Abbott Laboratories (U.S.)
  13.2.2. Alimera Sciences (U.S.)
  13.2.3. Allergan plc (Ireland.)
  13.2.4. Ampio Pharmaceuticals. (U.S.)
  13.2.5. Bayer AG (Germany)
  13.2.6. F. Hoffmann-La Roche (Switzerland)
  13.2.7. Novartis AG (Switzerland)
  13.2.8. Pfizer Inc. (U.S.)
  13.2.9. Regeneron Pharmaceuticals Inc. (U.S.)
  13.2.10. Valeant (Canada)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS